Education
About Us
Working with TipRanks
Follow Us
Siemens Healthineers AG Unsponsored ADR (SMMNY)
OTHER OTC:SMMNY
Top Page
Siemens Healthineers AG Unsponsored ADR
(OTC:SMMNY)
Select Model
Select Model
Rating:79Outperform
Price Target:
$32.00
▲(29.66% Upside)
Siemens Healthineers AG's strong financial performance and positive earnings call sentiment are the primary drivers of its stock score. The company's robust revenue growth, margin expansion, and strategic advancements outweigh the moderate valuation and neutral technical indicators. Challenges such as tariff impacts and market issues in China are notable but do not significantly detract from the overall positive outlook.
Siemens Healthineers AG Unsponsored ADR (SMMNY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$54.87B
Dividend Yield2.1%
Average Volume (3M)1.52K
Price to Earnings (P/E)23.2
Beta (1Y)1.02
Revenue Growth6.68%
EPS Growth12.49%
CountryUS
Employees72,000
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.39
Shares Outstanding2,256,000,000
10 Day Avg. Volume0
30 Day Avg. Volume1,521
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Siemens Healthineers AG Unsponsored ADR Business Overview & Revenue Model
Company DescriptionSiemens Healthineers AG, through its subsidiaries, develops, manufactures, and sells a range of diagnostic and therapeutic products and services to healthcare providers worldwide. The company operates through four segments: Imaging, Diagnostics, Varian, and Advanced Therapies. The Imaging segment provides magnetic resonance imaging, computed tomography, X-ray systems, molecular imaging, and ultrasound systems. The Diagnostics segment offers in-vitro diagnostic products and services to healthcare providers in laboratory, molecular and point-of-care diagnostics; and workflow solutions for laboratories and informatics products. The Varian segment provides cancer care technologies, and solutions and services to oncology departments in hospitals and clinics; and technology-enabled optimized workflows, clinical services and consulting capabilities, and digital solutions and applications for managing treatment and therapy. The Advanced Therapies segment offers products that are designed to support image-guided minimally invasive treatments in various areas, such as cardiology, interventional radiology, and surgery; and angiography systems and mobile C-arms, including a robotic-assisted platform for endovascular coronary and peripheral vascular interventions. It also provides equipment performance management, clinical education and e-learning, asset management, and managed departmental services for laboratories and healthcare facilities, as well as consulting and digital health services. The company is headquartered in Erlangen, Germany. Siemens Healthineers AG operates as a subsidiary of Siemens Aktiengesellschaft.
How the Company Makes MoneySiemens Healthineers generates revenue through multiple key streams, primarily from the sale of medical devices and imaging equipment, along with diagnostic products and services. Their Imaging segment, which includes MRI, CT, and ultrasound systems, forms a significant portion of their revenue, driven by demand for advanced imaging solutions in hospitals and clinics. In addition to hardware sales, the company earns revenue through software solutions and digital health applications that enhance medical imaging and diagnostics. Furthermore, Siemens Healthineers provides maintenance services and support for its products, contributing to recurring revenue. The company also engages in strategic partnerships and collaborations with healthcare providers and technology firms, which can lead to joint ventures and co-development of new technologies, thereby expanding their market reach and boosting revenues.
Siemens Healthineers AG Unsponsored ADR Earnings Call Summary
Earnings Call Date:Nov 05, 2025
(Q4-2025)
| % Change Since: |
Next Earnings Date:Jan 29, 2026
Earnings Call Sentiment Neutral
The earnings call highlights Siemens Healthineers' strong performance in fiscal year '25, achieving the upper end of their guidance, with significant growth in Imaging, Varian, and Advanced Therapies. However, challenges in China, tariff impacts, and lower revenue guidance for Q1 2026 present notable concerns.Q4-2025 Updates
Positive Updates
Achievement of Guidance and Revenue Growth
Siemens Healthineers closed fiscal year '25 successfully, achieving the upper end of their guidance range with broad-based growth in all regions except China. An overall book-to-bill ratio of 1.14 was reported for the fiscal year.
Impressive Segment Performance
Revenue from Imaging, Varian, and Advanced Therapies increased by almost 8%, with Imaging showing continued margin expansion. Varian has grown every year by at least high single-digit percentages since the combination, and Advanced Therapies maintained solid growth by keeping margins stable.
Free Cash Flow Improvement
Siemens Healthineers improved its free cash flow throughout the year, lowering leverage to 2.8x EBITDA, and announced a proposed dividend increase to EUR 1.
Strong Performance of Photon Counting CT and PETNET
Photon Counting CT and PETNET were highlighted as strong growth drivers in Imaging, contributing to a 6.5% revenue increase versus tough prior year comparisons.
Negative Updates
Challenges in China
Revenue in China remained flat at around EUR 620 million with no sign of sustained market recovery. Volume-based procurement in Diagnostics in China led to flattish year-over-year revenue.
Tariff and Foreign Exchange Headwinds
Tariffs and foreign exchange fluctuations negatively impacted margins, with an estimated headwind of EUR 0.15 in earnings per share year-over-year due to currency effects and an additional EUR 0.15 due to tariffs.
Lower Revenue Guidance for Q1 2026
Siemens Healthineers expects Q1 2026 revenue growth to be below the outlook range of 5% to 6%, with margins expected to be below the prior year quarter due to tariffs and foreign exchange impacts.
Company Guidance
In the recent Siemens Healthineers Q4 2025 earnings call, the company reported strong performance, achieving growth at the upper end of its guidance range. The book-to-bill ratio for the fiscal year was 1.14, indicating healthy demand globally, except in China. Adjusted EPS was within the upper half of the outlook range, with free cash flow improvements leading to a leverage of 2.8x EBITDA. Revenue growth was driven by a nearly 8% increase in segments like Imaging, Varian, and Advanced Therapies. Despite market challenges in China, Diagnostics showed a significant step change in profitability. For fiscal year 2026, Siemens Healthineers anticipates a 5% to 6% revenue increase, with adjusted EPS expected to be between EUR 2.20 and EUR 2.40, considering macroeconomic challenges like currency fluctuations and tariffs. The company remains optimistic about its strategic initiatives and upcoming Capital Markets Day, where further growth strategies and innovations will be discussed.Siemens Healthineers AG Unsponsored ADR Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
78
Positive
Cash Flow
80
Positive
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 22.36B | 21.68B | 21.71B | 18.00B | 14.46B |
| Gross Profit | 8.47B | 7.71B | 8.14B | 6.95B | 5.58B |
| EBITDA | 4.22B | 3.78B | 4.26B | 3.52B | 2.84B |
| Net Income | 1.94B | 1.51B | 2.04B | 1.73B | 1.41B |
Balance Sheet | |||||
| Total Assets | 46.05B | 46.68B | 49.06B | 41.93B | 25.09B |
| Cash, Cash Equivalents and Short-Term Investments | 2.68B | 1.64B | 1.44B | 1.32B | 656.00M |
| Total Debt | 16.21B | 16.65B | 16.65B | 14.31B | 5.50B |
| Total Liabilities | 27.81B | 28.55B | 29.20B | 25.87B | 12.58B |
| Stockholders Equity | 18.20B | 18.08B | 19.84B | 16.04B | 12.50B |
Cash Flow | |||||
| Free Cash Flow | 1.77B | 971.00M | 1.40B | 2.11B | 1.25B |
| Operating Cash Flow | 2.47B | 1.81B | 2.26B | 2.78B | 1.80B |
| Investing Cash Flow | -666.00M | -1.07B | -868.00M | -14.14B | -1.91B |
| Financing Cash Flow | -1.30B | -380.00M | -1.40B | 11.99B | -126.00M |
Siemens Healthineers AG Unsponsored ADR Technical Analysis
Negative
24.68
Price Trends
26.63
Negative
27.05
Negative
27.05
Negative
Market Momentum
-0.66
Negative
39.60
Neutral
88.49
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SMMNY, the sentiment is Negative. The current price of 24.68 is below the 20-day moving average (MA) of 24.82, below the 50-day MA of 26.63, and below the 200-day MA of 27.05, indicating a bearish trend. The MACD of -0.66 indicates Negative momentum. The RSI at 39.60 is Neutral, neither overbought nor oversold. The STOCH value of 88.49 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SMMNY.
Siemens Healthineers AG Unsponsored ADR Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | $54.87B | 23.23 | 11.46% | 2.10% | 6.68% | 12.49% | |
79 Outperform | $146.79B | 52.72 | 12.66% | ― | 21.62% | 54.80% | |
78 Outperform | $219.65B | 15.84 | 30.62% | 1.88% | 6.37% | 142.39% | |
74 Outperform | $130.80B | 27.56 | 9.81% | 2.76% | 5.34% | 13.15% | |
70 Outperform | $140.23B | 48.15 | 14.04% | 0.92% | 10.95% | -18.32% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $26.86B | ― | ― | 3.32% | -0.76% | -55.03% |
* Healthcare Sector Average
SMMNY
Siemens Healthineers AG Unsponsored ADR
24.89
-2.01
-7.47%
ABT
Abbott Laboratories
125.40
11.95
10.53%
BSX
Boston Scientific
97.72
7.65
8.49%
PHG
Koninklijke Philips
26.66
1.24
4.88%
MDT
Medtronic
101.99
20.65
25.39%
SYK
Stryker
364.35
-17.21
-4.51%
Siemens Healthineers AG Unsponsored ADR Corporate Events
Siemens Healthineers Reports Strong Q3 2025 Results
Jul 30, 2025
Siemens Healthineers AG, a leading company in the healthcare sector, specializes in medical technology and offers a wide range of products and services in imaging, diagnostics, and advanced therapies. The company is known for its innovative solutions that enhance patient care worldwide.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.